SCHEMBL1758566

SCHEMBL1758566

OCc1ccc(OCCF)cn1

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
HRH3 Q9Y5N1 2/20 0.39
APP P05067 7/20 0.39
LTA4H P09960 1/20 0.36
RECQL P46063 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17941825 0.90 APP (0.49) APP
SCHEMBL23538182 0.85 CCR1 (0.34) HRH3LTA4H
SCHEMBL3334122 0.81 LTA4H (0.46) HRH3LTA4H
SCHEMBL11378355 0.81 HRH3 (0.42) HRH3LTA4H
SCHEMBL15109274 0.81 APP (0.42) ALDH1A1HRH3APPLTA4H
SCHEMBL11471063 0.81 LTA4H (0.46) ALDH1A1HRH3LTA4HCA12CA1
SCHEMBL11423013 0.80 HRH3 (0.41) HRH3LTA4H
SCHEMBL17544106 0.80 CBFB (0.46) HRH3LTA4H
Hydrochloric Acid SCHEMBL11382535 0.79 HRH3 (0.40) HRH3LTA4H
SCHEMBL23530082 0.79 HRH3 (0.40) HRH3LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606570-B2 Deuterated compounds and imaging agents for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2026-04-21 US disclosed
EP-4077306-B1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2025-05-07 EP disclosed
US-11992535-B2 Compounds and probes for imaging huntingtin protein CHDI FOUNDATION, INC. (US) 2024-05-28 US disclosed
EP-4329826-A1 DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2024-03-06 EP disclosed
EP-4320114-A1 ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2024-02-14 EP disclosed
CN-117545512-A Deuterated compounds and imaging agents for imaging huntingtin CHDI基金会股份有限公司 2024-02-09 CN disclosed
CN-117412960-A Isoindolinone compounds and imaging agents for imaging huntingtin CHDI基金会股份有限公司 2024-01-16 CN disclosed
US-20220372045-A1 DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2022-11-24 US disclosed
US-20220372045-A1 DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2022-11-24 US disclosed
WO-2022232121-A1 DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2022-11-03 WO disclosed
WO-2022216947-A1 ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2022-10-13 WO disclosed
US-20210236663-A1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2021-08-05 US disclosed
US-20210236663-A1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. 2021-08-05 US disclosed
WO-2021127265-A1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2021-06-24 WO disclosed
WO-2021127265-A1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2021-06-24 WO disclosed
US-8852554-B2 Radiolabelled PDE10 ligands JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
EP-2493513-B1 RADIOLABELLED PDE10 LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2014-07-30 EP disclosed
EP-2493513-A1 RADIOLABELLED PDE10 LIGANDS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP disclosed
US-20120213703-A1 RADIOLABELLED PDE10 LIGANDS JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) 2012-08-23 US disclosed
WO-2011051324-A1 RADIOLABELLED PDE10 LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210236663-A1 COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 ALDH1A1 4528/4885HRH3 3299/4885APP 67/4885
US-12606570-B2 Deuterated compounds and imaging agents for imaging huntingtin protein HTT, HYPK, ATXN2 ALDH1A1 4171/4885HRH3 3467/4885APP 14/4885
US-20220372045-A1 DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HIRIP3 ALDH1A1 4688/4885HRH3 1619/4885APP 101/4885
US-11992535-B2 Compounds and probes for imaging huntingtin protein HTT, HYPK, HSPBP1 ALDH1A1 4528/4885HRH3 3299/4885APP 67/4885
US-20120213703-A1 RADIOLABELLED PDE10 LIGANDS PDE9A, PDE10A, PDE7A ALDH1A1 1265/4885HRH3 2887/4885APP 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.